Donate For Public and Patients Store Search

S064 - Laser Complications/Filler/Surgical - It's Complicated

Monday, March 4; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Treat potential surgical complications including bleeding, infection, dehiscence, recurrence, free-margin and scar abnormalities
  • Treat potential injectable and peel complications including neuromodulator asymmetry and migration, to filler nodules and necrosis, to peel infection and scarring.
  • Treat potential device complications including non-ablative lasers, ablative resurfacing lasers, lifting and tightening devices, as well as fat removal devices.

Description

Packing in a wide-range of dermatologic surgical procedures, this session will identify major areas of complications as well as treatment options. For dermatologic surgical procedures, topics will include: bleeding, infection, dehiscence, pin-cushioning, free-margin issues, nerve injury, scar revision and recurrent tumors. For injectable and peel procedures, major focus will be placed on the following: neuromodulator asymmetry and migration, filler nodules and necrosis, and peel scarring and pigment alteration. For lasers and devices, there will be a full-spectrum of concerns addressed: non-ablative laser and tattoo issues, resurfacing, lifting and tightening, and non-invasive fat removal complications.

Disclosures

  • Avram, Mathew M., MD, JD: Alastin Skincare, Inc – C(Fees); Allergan, Inc – C(Fees); Cytrellis Biosystems, Inc – C(ST); Invasix – C(Fees); Masters of Aesthetics, Inc. – F(Fees); Merz Aesthetics – C(Fees); Sciton Inc. – A(Fees); Sienna Biopharmaceuticals – A(Fees); Zalea, LLC – C(Fees); Zeltiq Aesthetics – C(Fees);
  • Cohen, Joel Lee, MD: Allergan, Inc. – C(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sciton Inc. – C(H);
  • Council, Martha Laurin, MD: Sanofi/Regeneron – C(H);
  • Green, Jeremy, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – A(H), I(Grants/Research Funding), SP(H); Bonti – A(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Candesant Biomedical, Inc. – I(Grants/Research Funding), SH(ST); Clarisonic – A(H); Cutera, Inc. – SP(H); Cynosure, Inc. – SP(EQ); Endo International plc – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), SP(H); Galderma USA – A(H); Lutronic – I(Grants/Research Funding); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(H); Pulse Biosciences – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(H), I(Grants/Research Funding); Sienna Labs, Inc. – A(H), I(Grants/Research Funding);
  • Kazin, Rebecca A., MD: Allergan, Inc – SH(ST); Galderma USA – SP(H); Merz Aesthetics – SP(H); Solta Medical Inc – SP(H); Suneva Medical, Inc. – SP(H);
  • Ortiz, Arisa, MD: Aerolase – A(H), O(EQ); Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – C(H); Guthy-Renker – SP(S); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Sienna Biopharmaceuticals – I(Grants/Research Funding); Ulthera – Data Safety Monitoring Board(H);
  • Ozog, David M., MD: Biofrontera AG – I(Grants/Research Funding), SH(NC); Galderma USA – I(Grants/Research Funding); miRagen Therapeutics, Inc. – I(Grants/Research Funding);
  • Rohrer, Thomas E., MD: Allergan, Inc. – I(Grants/Research Funding); Candela Corporation – A(H), SP(H); Medicis Pharmaceutical Corporation – SP(H); Merz Pharmaceuticals, LLC – I(H); Pulse Biosciences – A(H); Ulthera – I(H);
Schedule
Monday, March 4
1:00 PM
Dr. Council / Surgical: anesthesia safety, nerve injury, recurrent tumor, eye safety, antibiotic prophlaxis
1:20 PM
Dr. Ozog / Surgical: bleeding, infection, dehiscence, pin-cushioning, allergic contact dermatitis
1:40 PM
Dr. Rohrer / Filler Nodules
2:00 PM
Dr. Cohen / Filler Necroses
2:20 PM
Dr. Green / Laser: Non-ablative and tattoo complications
2:40 PM
Dr. Cohen / Laser: Ablative resurfacing complications
3:00 PM
Dr. Kazin / Chemical Peels
3:20 PM
Dr. Avram / Non-Invasive Fat Removal
3:40 PM
Dr. Ortiz / RF, lifting, and Tightening devices
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 204A
  • CME Credits
    3.00
  • Type
    Restricted
    New
Directors/Co-Directors
  • Joel Lee Cohen, MD, FAAD
Speakers
  • Arisa Ortiz, MD, FAAD
  • David M. Ozog, MD, FAAD
  • Jeremy Green, MD, FAAD
  • Martha Laurin Council, MD, FAAD
  • Mathew M. Avram, MD, JD, FAAD
  • Rebecca A. Kazin, MD, FAAD - Handout
  • Thomas E. Rohrer, MD, FAAD